Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 6, 2023; 11(1): 47-56
Published online Jan 6, 2023. doi: 10.12998/wjcc.v11.i1.47
Intestinal microecology-based treatment for inflammatory bowel disease: Progress and prospects
Xia-Xiao Yan, Dong Wu
Xia-Xiao Yan, Dong Wu, Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China
Author contributions: Yan XX and Wu D collected the data and wrote the paper. Both authors approved the final version to be published.
Supported by CAMS Innovation Fund for Medical Sciences, No. 2022-I2M-1-003.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong Wu, MD, Associate Professor, Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing 100730, China. wudong061002@aliyun.com
Received: September 7, 2022
Peer-review started: September 7, 2022
First decision: October 30, 2022
Revised: November 14, 2022
Accepted: December 15, 2022
Article in press: December 15, 2022
Published online: January 6, 2023
Processing time: 119 Days and 12.7 Hours
Abstract

Inflammatory bowel disease (IBD) is a chronic, recurrent, and debilitating disorder, and includes Crohn’s disease and ulcerative colitis. The pathogenesis of IBD is closely associated with intestinal dysbiosis, but has not yet been fully clarified. Genetic and environmental factors can influence IBD patients’ gut microbiota and metabolism, disrupt intestinal barriers, and trigger abnormal immune responses. Studies have reported the alteration of gut microbiota and metabolites in IBD, providing the basis for potential therapeutic options. Intestinal microbiota-based treatments such as pre/probiotics, metabolite supplementation, and fecal microbiota transplantation have been extensively studied, but their clinical efficacy remains controversial. Repairing the intestinal barrier and promoting mucosal healing have also been proposed. We here review the current clinical trials on intestinal microecology and discuss the prospect of research and practice in this field.

Keywords: Inflammatory bowel disease; Probiotics; Prebiotics; Intestinal metabolites; Fecal microbiota transplantation; Intestinal barrier

Core Tip: The intestinal microecological system plays an important role in the pathogenesis of inflammatory bowel disease (IBD). Reconstructing healthy intestinal microecology is a promising therapeutic strategy, but has not been widely accepted in the routine management of IBD. We herein discuss the progress and prospects of studies on IBD treatment targeting the intestinal microecological system, including disordered gut microbiota, metabolites, and intestinal epithelium.